IndustryCompany release

Zoetis trims full-year revenue range but lifts adjusted EPS guidance after 1% third-quarter dip

🇺🇸 Zoetis Inc. (ZTS) · Thu 05 Nov 2026

The animal health company reported third-quarter revenue of $2.4B, with US companion animal sales down 8%, and flagged new FDA actions including a screwworm emergency authorisation for Simparica Trio.

Zoetis reported third-quarter 2026 results on 5 November, with revenue of $2.4B, a 1% decline on the prior-year period. The company said weakness in US companion animal sales offset growth elsewhere in the business.

US companion animal sales fell 8%. The company attributed the decline to price sensitivity, competition in dermatology and generic products. Livestock and international sales both grew over the quarter.

For the full year, Zoetis narrowed its revenue guidance to $9.22B-$9.32B and raised its adjusted earnings-per-share guidance to $6.25-$6.35.

On the regulatory front, the company noted that the US Food and Drug Administration approved Convenia RTU for Dogs in October. It also pointed to an FDA Emergency Use Authorization for Simparica Trio against New World screwworm in dogs, along with several approvals outside the US. The summary available does not give further detail on those ex-US approvals.

As general context, an Emergency Use Authorization allows a product to be used under defined conditions in response to an urgent need, and is distinct from a full marketing approval.

What it means for your team

  • Animal health market-access teams should note the reported US companion animal pressure from price sensitivity, dermatology competition and generics.
  • Regulatory teams tracking veterinary products should record the October FDA approval of Convenia RTU for Dogs.
  • The Emergency Use Authorization for Simparica Trio against New World screwworm in dogs is a time-sensitive, conditional pathway rather than a standard approval, so its scope and conditions merit review.
  • Growth in livestock and international sales alongside several ex-US approvals suggests geographic diversification remains a feature of the company's portfolio.

Company's press release (SEC filing): Zoetis Inc. ↗

Article written by VigiEye from the official source (Zoetis Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →